On March 29, 2022 BioCurity is a private preclinical biotech company developing supportive cancer oncology drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients (Press release, BioCurity Pharmaceuticals, MAR 29, 2022, View Source [SID1234611140]). BioCurity reported the Company received a notice of allowance of claims from the United States Patent and Trademark Office for the Company’s United States patent that covers the use of the Company’s cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of radiation therapy and chemotherapy as part of their treatment regimen .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new patent builds upon the 8 US patents BioCurity exclusively controls related to its novel drug development. BioCurity also exclusively controls its international patents, which currently exist in Australia, China, Europe, Hong Kong, Japan, and Mexico, and cover the use of the Company’s cerium oxide nanoparticle technology for patients with certain cancers treated with radiation combined with chemotherapy.

Globally, it is estimated that 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The short and long-term side effects of radiation therapy to various organs and tissues in humans have been well characterized, can impair a cancer patient’s medical treatment plan, and can leave cancer survivors with permanent adverse conditions. Treatment of these side effects cost more than 3 billion dollars annually in the US. The global cancer supportive care market is projected to reach approximately 41 billion dollars by 2027 and is driven by the growing prevalence of cancer.

"BioCurity’s scientific discovery in an IV formulation for internal tissue as well as a topical formulation to protect against skin damage offers the potential to prevent the often-devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients undergoing radiation therapy alone or in combination with chemotherapy to treat their cancer. Each of the formulations have been studied in various proof of concept animal models of head and neck, lung, breast, pancreatic, colorectal, and prostate cancer. The positive preclinical data in these animal models suggest the potential use in multiple types of cancers where radiation therapy is used alone or in conjunction with chemotherapy to treat cancer patients," said Dr. Cheryl Baker PhD, Scientific Co-Founder, and a Board member of BioCurity.

BioCurity’s clinical development team led by CSSi LifeSciences has an excellent track record in working with small and emerging biopharmaceutical companies to advance their lead drug products to and through commercialization. With 100% success in obtaining an Investigational New Drug and 500 successful drugs, diagnostics and devices commercialized.